APOE and Alzheimer disease: For instance, tau PET studies in Aβ+ patients across the AD clinical spectrum have shown a more medial temporal lobe (MTL)-dominant pattern of tau pathology in e4 carriers compared to non-carriers [16, 21] even after adjusting for global amyloid burden [22, 23]. This suggests that APOE genotype may influence disease progression even after amyloid positivity is reached.